CYTO
Altamira Therapeutics Ltd.
NASDAQ · Healthcare · Biotechnology · BM
$0.30
+0.00%Margins
Gross margin
195.7%
EBITDA margin
-571.7%
EBIT margin
505.5%
Net margin
4479.1%
FCF margin
3059.1%
867.9%
Return on equity
-255.2%
Return on assets
-108.8%
Return on invested capital
-0.06x
Asset turnover
-$13.4M
Cash from operations
$0.13
Cash per share
Margins, returns on capital and operating efficiency from the latest trailing period · Data as of Dec 1, 2023